首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL7 |
| Uniprot No | P13232 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-177aa |
| 氨基酸序列 | DCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDAN KEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRK PAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTK EH |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-7重组蛋白的文献概览(虚构示例，仅供参考格式)：
1. **文献名称**：*Recombinant IL-7 Enhances T Cell Recovery in Lymphopenic Patients*
**作者**：Fry TJ, Mackall CL
**摘要**：研究证明重组IL-7蛋白可通过激活JAK-STAT信号通路，促进化疗后或HIV感染患者的T细胞增殖，改善免疫重建。
2. **文献名称**：*IL-7 Receptor Signaling in Cancer Immunotherapy*
**作者**：Alves NL, van Leeuwen EMM
**摘要**：探讨重组IL-7在肿瘤微环境中增强CD8+ T细胞浸润及功能的作用，并评估其与PD-1抑制剂联用的协同抗肿瘤效果。
3. **文献名称**：*Structural Characterization of Recombinant Human IL-7*
**作者**：Venkitaraman AR, et al.
**摘要**：解析重组IL-7蛋白的三维结构，揭示其与IL-7Rα受体结合的关键表位，为优化工程化IL-7变体提供分子基础。
(注：以上文献为模拟内容，实际引用需核实真实数据库。)
Interleukin-7 (IL-7) is a critical cytokine essential for lymphocyte development, homeostasis, and immune regulation. Produced primarily by stromal cells in the bone marrow and thymus, IL-7 binds to its receptor (IL-7Rα paired with the common γ-chain, γc) to activate downstream signaling pathways such as JAK-STAT, PI3K-AKT, and MAPK. This interaction promotes the survival, proliferation, and differentiation of lymphoid progenitors, particularly during T-cell and B-cell development. Its role in maintaining naïve and memory T-cell pools underscores its importance in adaptive immunity.
Recombinant IL-7 protein is engineered using genetic modification techniques, often expressed in bacterial, yeast, or mammalian cell systems. Mammalian systems (e.g., CHO cells) are preferred for producing glycosylated, biologically active forms. The purified protein retains the functional properties of native IL-7. enabling research and therapeutic applications.
Clinically, recombinant IL-7 has shown promise in treating lymphopenia, a condition marked by low lymphocyte counts caused by chemotherapy, viral infections (e.g., HIV), or hematopoietic stem cell transplantation. By enhancing T-cell reconstitution, it may improve immune recovery in immunocompromised patients. In oncology, IL-7 is explored as an adjuvant to boost antitumor immunity, as it expands tumor-infiltrating lymphocytes and counteracts immunosuppressive microenvironments. However, its pro-inflammatory potential requires careful evaluation in autoimmune or hyperinflammatory contexts.
Despite its therapeutic potential, challenges remain, including optimizing dosing to balance efficacy with risks of excessive T-cell activation or cytokine release syndrome. Ongoing studies aim to refine delivery methods, such as pegylated formulations or gene therapy approaches, to prolong its half-life and stability. As a research tool, recombinant IL-7 aids in dissecting lymphoid biology and immune tolerance mechanisms, further bridging translational immunology.
×
